Takeda announced that Andy Plump, the architect of the company’s R&D overhaul, will retire next year. Takeda credited Plump with pushing closer collaboration with young biotechs and leaving behind a “lasting foundation,” as the company continues to shape its development strategy. The leadership change matters for partners and stakeholders because R&D organization and external partnering models can affect how quickly programs advance and how licensing deals are structured.